Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Psoriasis 3Prostatic Neoplasms 1Lymphoma, Follicular 1

Interventions

tofacitinib 7Etanercept 7Methotrexate 4Adalimumab 4deucravacitinib 3secukinumab 2apremilast 2Nivolumab 2sotrastaurin 1sodium luminolate 1purine 1ixekizumab 1fumaric acid 1calcipotriene 1cabozantinib 1baricitinib 1abrocitinib 1Vitamin D 1Vaccines 1Sulfasalazine 1Standard of Care 1Specimen Handling 1Saline Solution 1Practice Guidelines as Topic 1Platinum Compounds 1Methods 1Mesalamine 1Mercaptopurine 1Ipilimumab 1Interviews as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Psoriasis × deucravacitinib × Clear all
NCT07256015 2025-12-01

Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Bristol-Myers Squibb

Recruiting
200 enrolled
Lymphoid

Lymphoma, Follicular, Psoriasis

NCT06952465 2025-05-01

A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

Bristol-Myers Squibb

Active not recruiting
2,000 enrolled

Psoriasis

NCT06281106 2025-04-02

TYPP

Centre Hospitalier Universitaire Vaudois

Phase 2/3 Terminated
2 enrolled

Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡